nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—Redness—Tretinoin—peripheral nervous system neoplasm	0.0331	0.0335	CcSEcCtD
Methylnaltrexone—Redness—Isotretinoin—peripheral nervous system neoplasm	0.0331	0.0335	CcSEcCtD
Methylnaltrexone—Stinging—Isotretinoin—peripheral nervous system neoplasm	0.0275	0.0279	CcSEcCtD
Methylnaltrexone—Stinging—Tretinoin—peripheral nervous system neoplasm	0.0275	0.0279	CcSEcCtD
Methylnaltrexone—Redness—Alitretinoin—peripheral nervous system neoplasm	0.0251	0.0254	CcSEcCtD
Methylnaltrexone—Injection site reaction—Tretinoin—peripheral nervous system neoplasm	0.0222	0.0225	CcSEcCtD
Methylnaltrexone—Injection site reaction—Isotretinoin—peripheral nervous system neoplasm	0.0222	0.0225	CcSEcCtD
Methylnaltrexone—Injection site reaction—Melphalan—peripheral nervous system neoplasm	0.0219	0.0222	CcSEcCtD
Methylnaltrexone—Stinging—Alitretinoin—peripheral nervous system neoplasm	0.0209	0.0212	CcSEcCtD
Methylnaltrexone—Injection site reaction—Alitretinoin—peripheral nervous system neoplasm	0.0168	0.017	CcSEcCtD
Methylnaltrexone—Redness—Epirubicin—peripheral nervous system neoplasm	0.011	0.0111	CcSEcCtD
Methylnaltrexone—Redness—Doxorubicin—peripheral nervous system neoplasm	0.0101	0.0103	CcSEcCtD
Methylnaltrexone—Erythema—Tretinoin—peripheral nervous system neoplasm	0.00976	0.00989	CcSEcCtD
Methylnaltrexone—Erythema—Isotretinoin—peripheral nervous system neoplasm	0.00976	0.00989	CcSEcCtD
Methylnaltrexone—Flatulence—Tretinoin—peripheral nervous system neoplasm	0.00961	0.00974	CcSEcCtD
Methylnaltrexone—Flatulence—Isotretinoin—peripheral nervous system neoplasm	0.00961	0.00974	CcSEcCtD
Methylnaltrexone—Stinging—Epirubicin—peripheral nervous system neoplasm	0.00913	0.00926	CcSEcCtD
Methylnaltrexone—Stinging—Doxorubicin—peripheral nervous system neoplasm	0.00845	0.00857	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Topotecan—peripheral nervous system neoplasm	0.00831	0.00843	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Tretinoin—peripheral nervous system neoplasm	0.00825	0.00836	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Isotretinoin—peripheral nervous system neoplasm	0.00825	0.00836	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Melphalan—peripheral nervous system neoplasm	0.00814	0.00825	CcSEcCtD
Methylnaltrexone—Erythema—Dactinomycin—peripheral nervous system neoplasm	0.00797	0.00808	CcSEcCtD
Methylnaltrexone—Oedema—Tretinoin—peripheral nervous system neoplasm	0.00796	0.00807	CcSEcCtD
Methylnaltrexone—Oedema—Isotretinoin—peripheral nervous system neoplasm	0.00796	0.00807	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Topotecan—peripheral nervous system neoplasm	0.00787	0.00798	CcSEcCtD
Methylnaltrexone—Oedema—Melphalan—peripheral nervous system neoplasm	0.00786	0.00797	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Tretinoin—peripheral nervous system neoplasm	0.00781	0.00791	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Isotretinoin—peripheral nervous system neoplasm	0.00781	0.00791	CcSEcCtD
Methylnaltrexone—Skin disorder—Topotecan—peripheral nervous system neoplasm	0.0078	0.0079	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Topotecan—peripheral nervous system neoplasm	0.00776	0.00786	CcSEcCtD
Methylnaltrexone—Skin disorder—Isotretinoin—peripheral nervous system neoplasm	0.00773	0.00784	CcSEcCtD
Methylnaltrexone—Skin disorder—Tretinoin—peripheral nervous system neoplasm	0.00773	0.00784	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Tretinoin—peripheral nervous system neoplasm	0.0077	0.0078	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Isotretinoin—peripheral nervous system neoplasm	0.0077	0.0078	CcSEcCtD
Methylnaltrexone—Skin disorder—Melphalan—peripheral nervous system neoplasm	0.00763	0.00774	CcSEcCtD
Methylnaltrexone—Erythema—Alitretinoin—peripheral nervous system neoplasm	0.00739	0.00749	CcSEcCtD
Methylnaltrexone—Injection site reaction—Epirubicin—peripheral nervous system neoplasm	0.00736	0.00746	CcSEcCtD
Methylnaltrexone—Flatulence—Alitretinoin—peripheral nervous system neoplasm	0.00729	0.00738	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.00693	0.00702	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.00687	0.00697	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.00687	0.00697	CcSEcCtD
Methylnaltrexone—Pain—Topotecan—peripheral nervous system neoplasm	0.00686	0.00696	CcSEcCtD
Methylnaltrexone—Pain—Tretinoin—peripheral nervous system neoplasm	0.00681	0.0069	CcSEcCtD
Methylnaltrexone—Pain—Isotretinoin—peripheral nervous system neoplasm	0.00681	0.0069	CcSEcCtD
Methylnaltrexone—Injection site reaction—Doxorubicin—peripheral nervous system neoplasm	0.00681	0.0069	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.00678	0.00688	CcSEcCtD
Methylnaltrexone—Pain—Melphalan—peripheral nervous system neoplasm	0.00672	0.00681	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.00656	0.00665	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.00651	0.0066	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.00651	0.0066	CcSEcCtD
Methylnaltrexone—Oedema—Dactinomycin—peripheral nervous system neoplasm	0.00651	0.0066	CcSEcCtD
Methylnaltrexone—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.00634	0.00643	CcSEcCtD
Methylnaltrexone—Erythema—Cisplatin—peripheral nervous system neoplasm	0.0063	0.00638	CcSEcCtD
Methylnaltrexone—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.00629	0.00638	CcSEcCtD
Methylnaltrexone—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.00629	0.00638	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.00625	0.00634	CcSEcCtD
Methylnaltrexone—Flatulence—Cisplatin—peripheral nervous system neoplasm	0.00621	0.00629	CcSEcCtD
Methylnaltrexone—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.00603	0.00612	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.00592	0.006	CcSEcCtD
Methylnaltrexone—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.00586	0.00594	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Alitretinoin—peripheral nervous system neoplasm	0.00583	0.00591	CcSEcCtD
Methylnaltrexone—Oedema—Vincristine—peripheral nervous system neoplasm	0.00581	0.00589	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.0057	0.00578	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Vincristine—peripheral nervous system neoplasm	0.00562	0.0057	CcSEcCtD
Methylnaltrexone—Pain—Dactinomycin—peripheral nervous system neoplasm	0.00556	0.00564	CcSEcCtD
Methylnaltrexone—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00549	0.00557	CcSEcCtD
Methylnaltrexone—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.00545	0.00552	CcSEcCtD
Methylnaltrexone—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.00545	0.00552	CcSEcCtD
Methylnaltrexone—Naltrexone—ABCB1—peripheral nervous system neoplasm	0.00543	0.406	CrCbGaD
Methylnaltrexone—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.00538	0.00545	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.00533	0.0054	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.00532	0.00539	CcSEcCtD
Methylnaltrexone—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00531	0.00538	CcSEcCtD
Methylnaltrexone—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00526	0.00534	CcSEcCtD
Methylnaltrexone—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00526	0.00534	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.00521	0.00528	CcSEcCtD
Methylnaltrexone—Pain—Alitretinoin—peripheral nervous system neoplasm	0.00516	0.00523	CcSEcCtD
Methylnaltrexone—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.00514	0.00521	CcSEcCtD
Methylnaltrexone—Oedema—Cisplatin—peripheral nervous system neoplasm	0.00514	0.00521	CcSEcCtD
Methylnaltrexone—Vomiting—Topotecan—peripheral nervous system neoplasm	0.0051	0.00517	CcSEcCtD
Methylnaltrexone—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.00506	0.00513	CcSEcCtD
Methylnaltrexone—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.00506	0.00513	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.00504	0.00511	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.00502	0.00509	CcSEcCtD
Methylnaltrexone—Vomiting—Melphalan—peripheral nervous system neoplasm	0.005	0.00506	CcSEcCtD
Methylnaltrexone—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.00499	0.00506	CcSEcCtD
Methylnaltrexone—Pain—Vincristine—peripheral nervous system neoplasm	0.00497	0.00504	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.00497	0.00504	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00493	0.005	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.00488	0.00495	CcSEcCtD
Methylnaltrexone—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.00477	0.00483	CcSEcCtD
Methylnaltrexone—Nausea—Topotecan—peripheral nervous system neoplasm	0.00477	0.00483	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.00475	0.00482	CcSEcCtD
Methylnaltrexone—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00473	0.00479	CcSEcCtD
Methylnaltrexone—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00473	0.00479	CcSEcCtD
Methylnaltrexone—Nausea—Melphalan—peripheral nervous system neoplasm	0.00467	0.00473	CcSEcCtD
Methylnaltrexone—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.0046	0.00466	CcSEcCtD
Methylnaltrexone—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.00457	0.00464	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.00455	0.00461	CcSEcCtD
Methylnaltrexone—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.00445	0.00451	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.00444	0.0045	CcSEcCtD
Methylnaltrexone—Pain—Cisplatin—peripheral nervous system neoplasm	0.0044	0.00446	CcSEcCtD
Methylnaltrexone—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00414	0.00419	CcSEcCtD
Methylnaltrexone—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.00413	0.00418	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.00407	0.00412	CcSEcCtD
Methylnaltrexone—Pain—Etoposide—peripheral nervous system neoplasm	0.00403	0.00408	CcSEcCtD
Methylnaltrexone—Buprenorphine—ABCB1—peripheral nervous system neoplasm	0.00399	0.298	CrCbGaD
Methylnaltrexone—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.00399	0.00404	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00398	0.00403	CcSEcCtD
Methylnaltrexone—Naloxone—ABCB1—peripheral nervous system neoplasm	0.00396	0.296	CrCbGaD
Methylnaltrexone—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00387	0.00392	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.00385	0.0039	CcSEcCtD
Methylnaltrexone—Dizziness—Vincristine—peripheral nervous system neoplasm	0.00384	0.0039	CcSEcCtD
Methylnaltrexone—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00384	0.00389	CcSEcCtD
Methylnaltrexone—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.00372	0.00377	CcSEcCtD
Methylnaltrexone—Vomiting—Vincristine—peripheral nervous system neoplasm	0.0037	0.00375	CcSEcCtD
Methylnaltrexone—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00358	0.00363	CcSEcCtD
Methylnaltrexone—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.00352	0.00357	CcSEcCtD
Methylnaltrexone—Nausea—Vincristine—peripheral nervous system neoplasm	0.00345	0.0035	CcSEcCtD
Methylnaltrexone—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00327	0.00331	CcSEcCtD
Methylnaltrexone—Erythema—Epirubicin—peripheral nervous system neoplasm	0.00323	0.00328	CcSEcCtD
Methylnaltrexone—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.00322	0.00327	CcSEcCtD
Methylnaltrexone—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.00319	0.00323	CcSEcCtD
Methylnaltrexone—Dizziness—Etoposide—peripheral nervous system neoplasm	0.00311	0.00316	CcSEcCtD
Methylnaltrexone—Nausea—Cisplatin—peripheral nervous system neoplasm	0.00305	0.0031	CcSEcCtD
Methylnaltrexone—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00299	0.00304	CcSEcCtD
Methylnaltrexone—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.00299	0.00303	CcSEcCtD
Methylnaltrexone—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.00295	0.00299	CcSEcCtD
Methylnaltrexone—Nausea—Etoposide—peripheral nervous system neoplasm	0.0028	0.00284	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.00274	0.00277	CcSEcCtD
Methylnaltrexone—Oedema—Epirubicin—peripheral nervous system neoplasm	0.00264	0.00268	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.00259	0.00262	CcSEcCtD
Methylnaltrexone—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.00256	0.0026	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.00255	0.00259	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.00253	0.00257	CcSEcCtD
Methylnaltrexone—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.00244	0.00248	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.0024	0.00243	CcSEcCtD
Methylnaltrexone—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.00237	0.0024	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.00236	0.00239	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00228	0.00231	CcSEcCtD
Methylnaltrexone—Pain—Epirubicin—peripheral nervous system neoplasm	0.00226	0.00229	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.00216	0.00219	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00211	0.00214	CcSEcCtD
Methylnaltrexone—Pain—Doxorubicin—peripheral nervous system neoplasm	0.00209	0.00212	CcSEcCtD
Methylnaltrexone—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.00209	0.00212	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.002	0.00202	CcSEcCtD
Methylnaltrexone—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.00193	0.00196	CcSEcCtD
Methylnaltrexone—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.00181	0.00183	CcSEcCtD
Methylnaltrexone—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.00175	0.00177	CcSEcCtD
Methylnaltrexone—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.00168	0.0017	CcSEcCtD
Methylnaltrexone—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.00167	0.00169	CcSEcCtD
Methylnaltrexone—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.00162	0.00164	CcSEcCtD
Methylnaltrexone—Nausea—Epirubicin—peripheral nervous system neoplasm	0.00157	0.00159	CcSEcCtD
Methylnaltrexone—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.00155	0.00157	CcSEcCtD
Methylnaltrexone—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.00145	0.00147	CcSEcCtD
